Overview

Topical Immuonosuppressant Drugs in Spring Catarrh

Status:
Not yet recruiting

Trial end date:
2022-02-01

Target enrollment:
0

Participant gender:
All

Summary

Spring catarrh is a prevalent type of conjunctival allergic disorder in temperate countries. Topical steroids are the cornerstone management of spring catarrh beside other anti allergic drugs. However, prolonged use of topical steroids especqially in resistant spring catarrh carries risk of ocular side effects as 2nd glaucoma and cataract. We will investigate the safety and efficacy of topical immuonosuppressant in the management of resistant spring catarrh as an alternative to steroid therapy.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Assiut University

Treatments:

Cyclosporine
Cyclosporins
Prednisolone

Criteria

Inclusion Criteria:

- Patients suffering from Vernal Keratoconjunctivitis refractory to conventional
treatments (Topical Anti-histaminic agents, Mast-cell stabilizer and steroids) are
included.

Exclusion Criteria:

- Contact lens wearer. Patient with one functioning eye. Patients with any other active
ocular inflammatory conditions. Patients with hypersentivity reaction to either
Cyclosporine A or Tacrolimus. Loss of 2 or more follow up visits.